Vanda Pharmaceuticals Faces FDA Rejection of HETLIOZ® Amid Ongoing Regulatory Dispute
- Vanda Pharmaceuticals faces FDA rejection of HETLIOZ® for jet lag disorder, citing insufficient evidence of effectiveness.
- The company disputes the FDA's findings, asserting its study models reflect real jet lag conditions.
- Vanda remains committed to addressing FDA concerns while continuing research on circadian rhythm disorders and sleep medicine.
FDA’s Rejection of HETLIOZ® Sparks Ongoing Dispute for Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc. faces a significant setback following the U.S. Food and Drug Administration's (FDA) rejection of its supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon), intended for treating jet lag disorder. The FDA issues a decision letter on January 8, 2026, acknowledging positive efficacy results from Vanda's controlled clinical trials but concludes that the data does not provide substantial evidence of effectiveness. The regulatory body argues that the phase advance protocols used in Vanda's studies fail to accurately simulate the complexities of actual jet travel, which includes factors such as reduced oxygen pressure, noise, and lighting changes—all elements that impact circadian rhythms significantly.
Vanda Pharmaceuticals disputes the FDA’s findings, asserting that the phase advance models adequately represent the core circadian misalignment associated with eastward jet lag, in line with the International Classification of Sleep Disorders (ICSD-3) criteria. The company points to evidence from its studies, which include both simulated and actual transatlantic travel, to demonstrate the efficacy of tasimelteon in enhancing sleep duration and alertness the following day. Vanda emphasizes the drug’s established safety profile, noting that it has been available in the market for over a decade and is associated with predominantly mild adverse events.
The backdrop to this latest decision includes a D.C. Circuit ruling from August 2025, which criticized the FDA's previous refusal to approve HETLIOZ® and underscored the importance of Vanda's evidence. Following this ruling, Vanda entered into a collaborative framework agreement with the FDA in October 2025, aimed at an expedited re-review of the application by January 7, 2026. Despite the FDA's current stance, Vanda expresses gratitude for the agency’s engagement and remains committed to constructive collaboration, although it believes the rejection does not fully align with the court's concerns.
In parallel developments, Vanda continues to prioritize its commitment to enhancing the understanding of circadian rhythm disorders and exploring additional therapeutic avenues. The company’s ongoing research efforts aim to solidify its position as a leader in sleep medicine, even as it navigates regulatory challenges. As Vanda maintains its focus on innovation, industry experts will be watching closely to see how it addresses the FDA's concerns and advances its product pipeline for circadian-related therapies.